Skip to content
Open access

Reducing the Burden of Hypoglycemia in Type 1 Diabetes: The Impact of FLO23011 on Patient-Reported Outcomes and Glycemic Correlates of Treatment Response.

Nov 2026 · Diabetes Therapy · 0 citations · 24 references
Medicine

Abstract

INTRODUCTION The aim of this study was to compare patient-reported outcomes (PROs) related to hypoglycemia recovery with FLO23011, a novel multi-energy substrate for hypoglycemia (MESH) recovery drink combining 15 g glucose with beta-hydroxybutyrate (BHB), versus standard glucose gel in adults with type 1 diabetes, and to explore associations between continuous glucose monitoring (CGM)-derived metrics and perceived and objective treatment response.

Methods

In a randomized, open-label, crossover study, 12 adults with type 1 diabetes used FLO23011 and standard glucose gel to treat hypoglycemia for two 6-week periods, with continuous glucose monitoring throughout. PROs were assessed using a study-specific 14-domain questionnaire and exit interviews. Exploratory CGM analyses examined patient-relevant recovery signals: glucose-band exposure versus psychological PRO scores, and baseline glycemic variability versus time-in-range (TIR) response.

Results

FLO23011 was rated more favorably than glucose gel in 13/14 domains. Among recovery-related items, 70% preferred FLO23011 for reduced aftereffects and 80% for return to daily activities; 82% preferred FLO23011 for sense of control, 73% for dosing confidence, and 64% for overall hypoglycemia management. In exit interviews, 92% rated FLO23011 "very/extremely" effective and 92% reported "never" or "rarely" experiencing post-hypoglycemia hangover symptoms with FLO23011. Participants described faster cognitive recovery, reduced disruption, and greater confidence. In exploratory analyses, reduced Level 1 hypoglycemia exposure was associated with higher reduced-worry and management-ability ratings (n = 5; ρ = 0.90; P = 0.037). Higher baseline coefficient of variation (CV) was associated with greater TIR improvement with FLO23011 (n = 9; ρ = 0.917; P = 0.0005).

Conclusions

FLO23011 was associated with more favorable patient-reported hypoglycemia recovery than glucose gel, with participants reporting benefits for aftereffects, daily functioning, and confidence. In exploratory CGM-PRO analyses, strong correlations in small subsets suggested that perceived benefit aligns with reduced Level 1 hypoglycemia exposure, and that baseline glycemic variability may predict objective response. These findings support evaluating hypoglycemia treatments on patient-reported recovery alongside glycemic outcomes. A graphical abstract is available with this article. TRIAL REGISTRATION ISRCTN Registry, ISRCTN19855666. Retrospectively registered, 11 June 2026.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.